Drug lookup | Fillwise

BREXPIPRAZOLE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules

StatusGeneral benefit

Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable

Aripiprazole (Abilify Asimtufii): general benefit
Cariprazine (Vraylar): general benefit
Paliperidone (Invega): general benefit
Paliperidone palmitate (Invega Sustenna): general benefit
Risperidone (Risperdal): general benefit, Not a benefit
Asenapine (Saphris): general benefit

18 more in the class list below

Rexulti · DIN 02461749 · 0.25mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461749 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 0.25 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94950 · Verify on the e-Formulary ↗ (DIN 02461749)

Source record

DIN 02461749: Rexulti Raw flags: sec3=Y Item: 281608344; group id 480; item number 1218; lccId None; manufacturer id OTS Source form: Tab; strength: 0.25mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461749 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94950

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461749

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rexulti · DIN 02461757 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461757 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 0.5 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02461757: Rexulti Raw flags: sec3=Y Item: 281608345; group id 480; item number 1219; lccId None; manufacturer id OTS Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461757 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94951

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rexulti · DIN 02461765 · 1mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461765 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 1 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02461765: Rexulti Raw flags: sec3=Y Item: 281608346; group id 480; item number 1220; lccId None; manufacturer id OTS Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461765 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94952

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rexulti · DIN 02461773 · 2mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461773 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 2 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02461773: Rexulti Raw flags: sec3=Y Item: 281608347; group id 480; item number 1221; lccId None; manufacturer id OTS Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461773 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94953

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rexulti · DIN 02461781 · 3mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461781 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 3 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02461781: Rexulti Raw flags: sec3=Y Item: 281608348; group id 480; item number 1222; lccId None; manufacturer id OTS Source form: Tab; strength: 3mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461781 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94954

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rexulti · DIN 02461803 · 4mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Rexulti · DIN 02461803 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2019-04-30 Health Canada: Marketed since 2017-04-19 · brand REXULTI · ATC N05AX16 BREXPIPRAZOLE · form Tablet · route Oral · ingredients BREXPIPRAZOLE 4 MG · company Otsuka pharmaceutical co ltd · schedule Prescription

Check this DIN again · Health Canada product record

Rexulti: Formulary list price $3.5000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02461803: Rexulti Raw flags: sec3=Y Item: 281608349; group id 480; item number 1223; lccId None; manufacturer id OTS Source form: Tab; strength: 4mg Recorded listing: General benefit Source prices (unrounded): $3.5000; ministry $3.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461803 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94955

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab

PALIPERIDONE PALMITATE

· 8 products · General benefit · strengths: 50mg, 75mg, 100mg, 150mg, 175mg/0.875mL, 263mg/1.315mL, 350mg/1.75mL, 525mg/2.625mL · Inj Pref Syr, Inj Susp-Pref Syr

RISPERIDONE

· 82 products · Listed, not a benefit (12), General benefit (70) · strengths: 1mg/mL, 0.5mg, 1mg, 2mg, 3mg, 4mg, 25mg, 37.5mg, 50mg, 0.25mg · O/L, Orally Disintegrating Tab, Pd for Inj-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: major depressive disorder, schizophrenia

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ASENAPINE, CARIPRAZINE, PALIPERIDONE PALMITATE, VORTIOXETINE HYDROBROMIDE ASENAPINE · General benefit INDICATIONS AND CLINICAL USE Adults: Schizophrenia SAPHRIS® (asenapine) sublingual tablet is indicated for the treatment of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00060860.PDF; date April 27, 2021; DIN 02374803; fetched 2026-09-10 Product monograph CARIPRAZINE · General benefit 1 INDICATIONS Schizophrenia VRAYLAR (cariprazine) is indicated for: • the treatment of schizophrenia in adults. PM: https://pdf.hres.ca/dpd_pm/00074842.PDF; date MAR 06, 2024; DIN 02526794; fetched 2026-09-10 Product monograph • the treatment of schizophrenia in adults. In controlled clinical trials, VRAYLAR was found to improve both positive and negative symptoms. PM: https://pdf.hres.ca/dpd_pm/00074842.PDF; date MAR 06, 2024; DIN 02526794; fetched 2026-09-10 Product monograph DESVENLAFAXINE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS PRISTIQ (desvenlafaxine succinate) is indicated for: • symptomatic relief of major depressive disorder in adults. PM: https://pdf.hres.ca/dpd_pm/00074568.PDF; date FEB 04, 2009; DIN 02321092; fetched 2026-09-10 Product monograph DULOXETINE · Listed, not a benefit (2), General benefit (36) 1 Indications pms-DULOXETINE (Duloxetine Delayed-Release Capsules) is indicated in adults for: • Major Depressive Disorder pms-DULOXETINE is indicated for the symptomatic relief of major depressive disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph FLUOXETINE HCL · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) 1 INDICATIONS pms-FLUOXETINE (fluoxetine) is indicated in adults for: • Depression: pms-FLUOXETINE is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00076968.PDF; date AUG 30, 2024; DIN 02177579; fetched 2026-09-10 Product monograph PALIPERIDONE PALMITATE · General benefit 1 INDICATIONS Adults INVEGA SUSTENNA® (paliperidone palmitate prolonged-release injectable suspension) is indicated for: • the treatment of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00072646.PDF; date June 30, 2010; DIN 02354217; fetched 2026-09-10 Product monograph VILAZODONE HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VIIBRYD (vilazodone hydrochloride tablets) is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00073801.PDF; date JUL 15, 2015; DIN 02443724; fetched 2026-09-10 Product monograph VORTIOXETINE HYDROBROMIDE · General benefit 1 Indications TRINTELLIX (vortioxetine hydrobromide) is indicated for: • the treatment of major depressive disorder (MDD) in adults. PM: https://pdf.hres.ca/dpd_pm/00085298.PDF; date 2026-07-10; DIN 02432919; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS REXULTI (brexpiprazole) is indicated for: • treatment of schizophrenia in adults. In clinical trials, REXULTI was found to significantly improve both positive and negative symptoms. • use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode (see 14.1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD). • symptomatic management of agitation associated with Alzheimer’s dementia (AAD) in patients with aggressive behaviour, unresponsive to non-pharmacological approaches. When considering the use of REXULTI as adjunctive treatment in MDD, clinicians must take into account the safety concerns associated with antipsychotic drugs, a class of drugs to which REXULTI belongs. Safety concerns of this class include: weight gain; hyperlipidemia; hyperglycaemia; tardive dyskinesia; and neuroleptic malignant syndrome (see 7 WARNINGS AND PRECAUTIONS, 8 ADVERSE REACTIONS). REXULTI should only be prescribed in patients with MDD by clinicians who are aware of the importance and are experienced in th… https://pdf.hres.ca/dpd_pm/00074327.PDF PM date: February 16, 2017 Source product: REXULTI; DIN 02461749; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.